Navigation Links
Intercept Pharmaceuticals Reports Third Quarter 2013 Financial Results
Date:11/14/2013

NEW YORK, Nov. 14, 2013 /PRNewswire/ -- Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases such as primary biliary cirrhosis, today reported financial results for the three and nine months ended September 30, 2013 and announced presentations at upcoming investor conferences.

Third Quarter 2013 Financial ResultsResults of OperationsNine Months Ended September 30, 2013

For the nine months ended September 30, 2013, Intercept reported a net loss of $55.4 million, or $3.15 per share, compared to a net loss of $15.5 million, or $4.64 per share, for the nine months ended September 30, 2012. The $39.9 million increase in net loss was primarily due to the increase in the non-cash charges related to the periodic revaluation of warrant liability of $29.6 million, which was primarily caused by the increase in the market price of Intercept's common stock, and an increase in non-cash stock-based compensation of $5.2 million.

Licensing revenue decreased by $825,000 to $1.2 million for the nine months ended September 30, 2013, compared to $2.0 million for the corresponding period of the prior year, because the up-front payment related to the Servier collaboration was fully amortized as of the third quarter of 2012, and therefore no amortized revenue related to this upfront payment was recognized in 2013.

Research and development expenses increased to $18.4 million for the nine months ended September 30, 2013 from $11.4 million for the corresponding period of the prior year, primarily as a result of increased activities in Intercept's development program for its product candidate, obeticholic acid (OCA).  The increase in R&D expense compared to the corresp
'/>"/>

SOURCE Intercept Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Intercept Pharmaceuticals Closes $30 Million Series C Financing
2. Intercept Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
3. Intercept Pharmaceuticals to Present at Deutsche Bank Healthcare Conference
4. Intercept Pharmaceuticals Announces Proposed Public Offering of Common Stock
5. Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock
6. Intercept Pharmaceuticals to Present at the Wedbush Securities Life Sciences Management Access Conference
7. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
8. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
9. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
10. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
11. Icahn Issues Statement Regarding Amylin Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... has witnessed robust development with the growth pace keeping at ... In 2012, the size of China ... worldwide soaring to 16.3%. It is projected that ... rate by around 20% in the upcoming years and that ... An integrated membrane industrial system has taken shape ...
(Date:12/17/2014)... , Dec. 17, 2014  Strategic Health Services, Inc. ... solutions, today announced a strategic agreement with QualCare, Inc., a ... New Jersey regional marketplace.  This agreement will ... health and wellness solutions QualCare brings to its clients ... surrounding region. QualCare plans cover more ...
(Date:12/17/2014)... December 17, 2014 , ... than a hub of information concerning the biopharmaceutical Group,s national ... A further addition to the recently launched institutional website that ... now been enriched by a new chapter in the fascinating ... A richly detailed and panoramic hub on the world of ...
Breaking Medicine Technology:Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 3Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 2Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 3Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3
... NEW YORK, April 27, 2011 ... biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments ... year,s Oncology Nursing Society (ONS) Congress at the Boston Convention ... booth (#652) will be displayed in the Exhibition Hall ...
... Medical Industries, Inc. (OTC: PDMI.PK) announced its success at ... which was held at the Houston Convention Center in ... practice optometrists from many of the most highly regarded ... the annual meeting.  The meeting provided opportunities for participating ...
Cached Medicine Technology:Access Pharmaceuticals to Attend the 36th Annual Oncology Nursing Society Congress 2Access Pharmaceuticals to Attend the 36th Annual Oncology Nursing Society Congress 3Paradigm is Successful at Annual Vision Source Meeting in Houston, Texas 2
(Date:12/20/2014)... Today, Balfleet.com, one of the most outstanding dressmakers ... off on its Mother of the Bride Dresses ... the bride dresses from Balfleet.com feature gorgeous looks and ... takes pride in providing high quality dresses to its ... discounts on our mother of the bride dresses, and ...
(Date:12/19/2014)... (PRWEB) December 20, 2014 Sweetdressy.com ... market, has introduced its newest selection of cheap prom ... are very popular in the world and clients can ... , Meanwhile, these prom dresses feature cool cuts and ... $200 now, targeting the middle-end market. Discount shipping costs ...
(Date:12/19/2014)... CA (PRWEB) December 19, 2014 ... corporation dedicated to developing educational events, tools and ... Rouxbe Cooking School , the world’s leading ... the prescription every human being needs: Culinary Rx. ... plant-based cooking course, Culinary Rx, scheduled for debut ...
(Date:12/19/2014)... Eufaula, Oklahoma, located just 9 miles ... state’s largest lake with more than 600 miles of ... a little more than 3,000 residents, hosted its annual ... 6th of December. , Featuring Santa, Christmas lights and ... on Main Street. Narconon Arrowhead’s parade float participated ...
(Date:12/19/2014)... (PRWEB) December 20, 2014 The Medspa ... new injectable filler from respected cosmetic brand Juvéderm. Voluma ... naturally with age. The Medspa at Hendrick is pleased ... in skin care technology to its clients. , Voluma ... to be FDA-approved to treat the mid-face and cheek ...
Breaking Medicine News(10 mins):Health News:Balfleet.com is Offering 50%-70% Off of its Mother of the Bride Dresses 2Health News:Cheap Prom Dresses Online Now at Sweetdressy.com 2Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 2Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 3Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 4Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 3Health News:Breakthrough New Injectable Dermal Filler Voluma XC Offered by The MedSpa at Hendrick 2
... ... a common technology infrastructure for Policy, Compliance, Risk, SOX, Internal Audits and IT ... ... -- MetricStream, Inc. (“MetricStream”), the market leader in the enterprise-wide Governance, Risk ...
... (NYSE Alternext: ULU), a specialty pharmaceutical company ... and oral care products, today announced it has entered into ... at a price per share of $0.14 pursuant to a ... of approximately $1.5 million. , Investors will also receive warrants ...
... Mass., Nov. 12 Cequent Pharmaceuticals, a pioneer in ... to prevent and treat human disease, has announced that ... application with the U.S. Food and Drug Administration (FDA). ... candidate, targets beta-catenin, a key oncogene implicated in the ...
... Nov. 12 Mary Elizabeth Derig, of Seattle, Washington, ... Edition for her outstanding contributions and achievements in the ... ) , ABOUT MARY ELIZABETH ... an extensive career as a Registered Nurse including work ...
... (NYSE: ABT ) announced today a definitive agreement to ... antibody to Nerve Growth Factor (NGF), expanding the company,s pain ... a novel biologic in Phase I clinical trial development that ... released at sites of tissue damage and inflammation, and plays ...
... ... Mary Alexander will present during Class Action/Mass Torts session discussing tainted food products , ... San Francisco, CA (PRWEB) November 12, ... product law firms in the nation, will take the podium during the 48th Annual Consumer ...
Cached Medicine News:Health News:Amedisys Selects MetricStream for Integrated Enterprise-wide GRC 2Health News:ULURU Inc. to Raise $1.5 Million in Registered Direct Offering 2Health News:Cequent Files its First IND with FDA: CEQ508, a tkRNAi Drug Candidate in Oncology 2Health News:Cequent Files its First IND with FDA: CEQ508, a tkRNAi Drug Candidate in Oncology 3Health News:Cequent Files its First IND with FDA: CEQ508, a tkRNAi Drug Candidate in Oncology 4Health News:Mary Elizabeth Derig Recognized by Strathmore's Who's Who Worldwide Publication 2Health News:Abbott to Acquire Novel Investigational Biologic to Treat Chronic Pain 2Health News:California Consumer Attorney Mary Alexander to Present at 48th Annual COAC Convention 2
... C-terminal cleavage product produced during processing of ... molecule. Although the C-peptide of insulin is ... or extra-renal metabolism and therefore has a ... In addition, C-peptide assays may be analytically ...
... C-peptide of insulin is the C-terminal cleavage ... prohormone to the mature insulin molecule. Although ... it does undergo significant liver or extra-renal ... circulating half-life than insulin [1]. In addition, ...
... 1-2% of circulating testosterone exists as unbound ... is bound to SHBG with high affinity ... to albumin. Both the albumin-bound and free ... effectively inhibits testosterone action. Measurement of the ...
... the first, easy-to-use, non-invasive diagnostic technology ... cardiac dysfunction including acute heart failure, ... cardiac conditions. Designed to seamlessly fit ... enable clinicians caring for cardiac patients ...
Medicine Products: